Press releases
-
-
-
-
-
Internal link ProQR Announces Results for the Second Quarter of 2016
-
-
Internal link ProQR to Release Topline Data from Proof of Concept Study of QR-010 in Cystic Fibrosis Patients at NACFC
-
Internal link ProQR’s Drug Candidate QR-110 for Leber’s Congenital Amaurosis Type 10 Receives EMA and FDA Orphan Drug Designation
-
Internal link ProQR Announces Presentations at the European CF Conference and the JMP Life Science Conference
-
Internal link ProQR Announces Results for the First Quarter of 2016
-
-
Internal link ProQR Announces Annual Meeting of Shareholders
-
-
-
-
-
Internal link ProQR Announces Results for the Third Quarter of 2015 and Provides Update on Clinical Trials
-
-
-
Internal link ProQR Announces a Proof-of-Concept Nasal Potential Difference Study of QR-010 is Open for Enrollment
-
Internal link ProQR Announces Results for the Second Quarter of 2015
-
Internal link ProQR Announces Enrollment Has Started in Global Phase 1b Study of QR-010 in Cystic Fibrosis Patients
-
-
-
Internal link ProQR Therapeutics Announces Annual Shareholder Meeting